Particularly, CCR8 antibodies capable of inducing antibody-dependent cellular cytotoxicity (ADCC) have demonstrated their ability to selectively eliminate TITRs within tumor sites, resulting in reduced tumor growth without causing side effects [3–6]. The gene discussed is CCR8; the disease is neoplasm.